Immunome, Inc.

NASDAQ:IMNM

Biotechnology

Healthcare
$16.61 -2.26%

-$0.42 today

Market cap
$1.96B
Beta
2.07
P/E (TTM)
-9.1
EPS (TTM)
-$1.99
52W Low $7.96High $27.65

Volume 0.88M

Average 1.23M

Returns on capital

Immunome, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-33.5%

avg -67.4%

ROIC

-33.5%

avg -134.2%

ROA

-31.1%

avg -105.7%

Analysis

ROA is currently the strongest return metric at -31.1% versus its period average of -105.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Clay Siegall

Chairman, President & Chief Executive OfficerUSD 1.41M65——

Max Rosett

Chief Financial OfficerUSD 1.16M3694.50K0.10%

Jack Higgins

Chief Scientific OfficerUSD 956.34K4656.25K0.06%

Robert J. Lechleider

Chief Medical OfficerUSD 850.09K65——

Sandra G. Stoneman

Chief Legal Officer, General Counsel & Corporate SecretaryUSD 715.35K5343.80K0.05%

Kinney Horn

Chief Business OfficerUSD 598.86K510<0.01%

Roee Shahar

Executive Vice President of Commercial————

Philip Tsai

Chief Technical Officer—5876.50K0.08%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 11, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

11

$2.31M

Sells

28

$27.51M

Net Transaction Value

−$25.20M

Net selling

Most Active

Barchas Isaac

12 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 11, 26

Higgins Jack

Direct

Sell$334.2K
Aug 12, 26

Barchas Isaac

Direct

Sell$301.1K
Aug 11, 26

Barchas Isaac

Indirect

Sell$1.6M
Aug 10, 26

Barchas Isaac

Indirect

Sell$264K
Aug 7, 26

Barchas Isaac

Indirect

Sell$397.4K
Aug 6, 26

Barchas Isaac

Indirect

Sell$543.1K
Aug 4, 26

Horn Kinney

Direct

Sell$2.3M
Jul 7, 26

Barchas Isaac

Indirect

Sell$409.1K
Jul 7, 26

Horn Kinney

Direct

Sell$27.3K
Jul 6, 26

Barchas Isaac

Indirect

Sell$2M

1–10 of 39

Summary

Insiders reported 11 buys worth $2.31M and 28 sells worth $27.51M over the last 12 months. That adds up to net selling of $25.20M. Barchas Isaac was the most active insider with 12 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A3 analysts
RevenueN/AN/AN/A
+141.6% (5yr)6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Forward estimates point to Revenue at +141.6% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Immunome, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about IMNM's management, answered from reported figures.

Who manages IMNM?

Immunome, Inc. (IMNM) lists 8 active executives. The top listed executive is Robert J. Lechleider, Chief Medical Officer.

Are IMNM insiders buying or selling?

Recent insider activity shows net buying of $77.67M.